Afimmune
Ireland - DublinBiotechnology
Focus: Afimmune is a private Irish biotech focused on bioactive lipid technology, targeting cardiovascular and metabolic diseases with a Phase 2 pipeline in NAFLD and hypertriglyceridemia.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
0
About Afimmune
AI assessmentNot HiringNo open roles listed right now. Follow Afimmune to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Afimmune's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Epeleuton
Non Alcoholic Fatty Liver DiseaseClinical Trials (3)
NCT02941549Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
Phase 2Help build intelligence for Afimmune
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.